$RUN

Jurich Lynn Michelle sold $680K of RUN

Jurich Lynn Michelle sold 50,000 shares of Sunrun Inc. (RUN) at $13.61 ($0.68M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jurich Lynn Michelle
Published Jul 1, 2026, 10:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RUN
Neutral
medium confidence
Mentioned
$RUN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RUNNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 50,000 shares at a stated price, with holdings after the trade and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Provides incremental sentiment/flow information for RUN, but lacks any operational or guidance catalyst.

03

What to watch

Traders may focus on the sale size, but the key nuance is the pre-arranged plan and director role, which usually dampens interpretive value.

Relevance 4/10Novelty 5/10Timing: filed 2026-07-01 (after-hours) for a same-day 10b5-1 sale

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Sunrun Inc. (RUN).

Company-level read

Ticker impact

$RUNNeutralMedium confidence
Context

Sunrun director Jurich Lynn Michelle filed a Form 4 selling 50,000 shares at $13.6064 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a director open-market sale with an explicit pre-arranged 10b5-1 plan, which typically reduces signal strength versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the transaction may be mechanically scheduled and not reflect bearish expectations; any price reaction could be overdone.

Key entities

  • Sunrun Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Jurich Lynn Michelle

    Director who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FSLRMed

First Solar Climbs 4% as Truist Buy Call and December Tariff Floor Reset Panel Pricing Outlook; Enphase Energy and Sunrun Hold Flat

First Solar (FSLR) stock rose 4% to $186.21 after a Truist upgrade to Buy with a $270 price target, citing improved pricing and valuation. The U.S. Department of Commerce's Section 232 trade decision sets a minimum import price for foreign solar panels, benefiting First Solar. Enphase (ENPH) and Sunrun (RUN) stocks remained flat. First Solar's thin-film technology and U.S. manufacturing position it favorably against competitors.

$RUNHigh

Goldman Sachs Cut Its Sunrun Target. It Still Sees [44%] Upside

Goldman Sachs and Citi reduced their price targets for Sunrun (RUN) to $11 and $14, respectively, while maintaining Buy ratings. Analysts anticipate a decline in Sunrun's EPS from $1.71 in 2025 to $1.00 by 2027. Sunrun's stock closed at $7.61 on Oct. 7, a 52-week low. The cuts reflect lower expectations for near-term growth and cash generation.

$RUNMed

Why is Sunrun stock sliding today?

Sunrun (RUN) stock fell 2.0% to $7.46 in pre-market trading, continuing a downtrend after price target cuts from Goldman Sachs and Citi, citing lower near-term growth expectations. The stock hit a 52-week low of $7.42, down 62% over the past year. Analysts maintained Buy ratings but reduced targets to $11 and $14, respectively. A large options trade suggests hedging against further downside. The broader market decline and policy uncertainty also weighed on the stock.